



MEDMIRA INC. NAMED TO 2005 TSX VENTURE 50 RANKED AS ONE OF CANADA'S TOP EMERGING PUBLIC COMPANIES

DECEMBER 6, 2005 (Halifax, Nova Scotia) – MedMira Inc., (“MedMira”) (TSX Venture: MIR, NASDAQ: MMIRF) the global market leader in flow-through rapid diagnostic tests was today named to the 2005 TSX Venture 50™, the first ever ranking of Canada’s top emerging public companies listed on TSX Venture Exchange.

“We are extremely pleased to be part of the TSX Venture 50 and named as one of the top five in the life science sector,” said Stephen Sham, chairman and CEO of MedMira. “Being recognized as one of Canada’s top performers is tremendous and important recognition of our accomplishments thus far.”

The TSX Venture 50 are the top 10 companies in each of five major industry sectors – mining, oil & gas, technology, life science and diversified industries – based on a ranking formula with equal weighting given to one-year revenue (last reported 12 months), return on investment, market cap growth and trading volume. All data was as of August 31, 2005.

“We are very proud to launch the TSX Venture 50 to celebrate the achievement of our issuers,” said Linda Hohol, President, TSX Venture Exchange. “The impressive list of companies demonstrates that the TSX Venture Exchange is a unique incubator of public companies, and the companies in the TSX Venture 50 are living proof as to why this market is working.”

The 2005 TSX Venture 50™ was compiled based on public historical data and is not an invitation to purchase securities listed on Toronto Stock Exchange and/or TSX Venture Exchange. TSX Group Inc. and its affiliates do not endorse or recommend any securities referenced in this ranking. Neither TSX Group Inc. nor its affiliated companies represent, warrant or guarantee the accuracy or the completeness of the information. You should not rely on this information contained herein for any trading, business or financial purposes. TSX Group Inc. and its affiliates assume no liability for any errors or inaccuracies herein or any use or reliance upon this information.

About MedMira

MedMira is the leading global manufacturer and marketer of in vitro flow-through rapid diagnostic tests. MedMira's tests provide reliable, rapid diagnosis in just 3 minutes for the detection of human antibodies in human serum, plasma or whole blood for diseases such as HIV and hepatitis C. Health Canada, the United States FDA and the SFDA in the People's Republic of China have approved MedMira's rapid HIV tests.

MedMira's rapid HIV tests are currently used in clinical laboratories, hospitals, and clinics where professional counselling and patient treatment are immediately available.

The MiraCare™ Rapid HIV Antibody Test, MedMira's over-the-counter (OTC) product, is available in pharmacies throughout Hong Kong and Macao Special Administrative Regions, in the People's Republic of China.

MedMira delivers rapid diagnostic solutions to healthcare communities around the globe. Its corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada with a representative office in Guilin, China.

This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement.

For more information visit MedMira's website at www.medmira.com.

-30-

Contacts:

Dr. James Smith
Investor Relations
Tel: 902-450-1588

E-mail: ir@medmira.com

Andrea Young
Corporate Communications
Tel. 902-450-1588
Email: ayoung@medmira.com